Herbal medicine for amyotrophic lateral sclerosis: A systematic review and meta-analysis

Yuebo Song1,2, Qiuyang Jia1,2, Xiaorui Guan1,2, Sugimoto Kazuo1,2,3, Jia Liu1,2, Weisong Duan4,5, Luda Feng1,2, Chi Zhang1* and Ying Gao1,2*

1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China, 2Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing, China, 3Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China, 4Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, China, 5Neurological Laboratory of Hebei Province, Shijiazhuang, China

Background: The effect of herbal medicine (HM) on amyotrophic lateral sclerosis (ALS) is controversial. Clinical trials investigating HMs continue; however, the use of HM is still questioned. We aimed to systematically review the literature pertaining to the effects and safety of HM in ALS.

Methods: Randomised controlled trials (RCTs) that investigated the efficacy of HMs in ALS patients compared to any types of controls were identified. Nine databases and six registers were searched from their inception dates to 25 March 2022. Per the PRISMA guidelines, trials were identified and extracted. The risk of bias was evaluated using the Cochrane's tool. Certainty of evidence was assessed as per the GRADE criteria. Forest plots were constructed to assess the effect size and corresponding 95% CIs using fixed-effect models, and random-effect models were employed when required. The primary outcome was the activity limitation measured by validated tools, such as the revised ALS Functional Rating Scale.

Results: Twenty studies (N = 1,218) were eligible. Of these, only five studies were double-blinded, and two were placebo-controlled. Fourteen HMs (fifty-one single botanicals) were involved; Astragalus mongholicus Bunge, Atractylodes macrocephala Koidz., and Glycyrrhiza glabra L. were commonly used in nine, eight, and six trials, respectively. For delaying activity limitation, Jiweiling injection (MD, 2.84; 95% CI, 1.21 to 4.46; p = 0.0006) and Shenmai injection (SMD, 1.07; 0.69 to 1.45; p < 0.00001) were significantly more efficacious than Riluzole, but the evidence was low quality. For ameliorating motor neuron loss, Jiweiling injection [right abductor pollicis brevis (APB): MD, 32.42; 7.91 to 56.93; p = 0.01 and left APB: MD, 34.44; 12.85 to 56.03; p = 0.002] was favoured, but the evidence was very low quality. Nine studies reported one hundred and twenty-three adverse events, twenty-six of which occurred in the treatment groups and ninety-seven in the control groups.

Conclusion: Very low to low quality of evidence suggests that HMs seem to produce superior treatment responses for ALS without increased risk of adverse events. Additional studies with homogeneous participants, reduced...
methodological issues, and more efficient outcome measures are required to provide confirmatory evidence.

**Systematic Review Registration:** https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42021277443.

**KEYWORDS**
amyotrophic lateral sclerosis, herbal medicine, motor neuron disease, meta-analysis, alternative and complementary medicine, systematic review

1 Introduction

As one of the diseases that modifying therapies are urgently needed, the effects of novel treatments such as herbal medicine (HM) on amyotrophic lateral sclerosis (ALS) are being broadly investigated. However, the various responses to HMs were questioned continually. ALS is a fatal, neurodegenerative disorder characterized by the progression of focal muscle weakness and wasting until respiratory failure within 3–5 years (Brown and Al-Chalabi, 2017). Motor neuron loss triggers activity limitation and reduces the quality of life (QOL) of patients with ALS. Currently, only two disease-modifying drugs are approved by the Food and Drug Administration for ALS treatment. Riluzole only slightly prolongs survival (Miller et al., 2002), and Edaravone is efficacious merely in patients who meet strict eligibility criteria (Abe et al., 2017). Because of the modest benefits of current therapies, many patients with ALS resort to HMs. According to a cross-sectional survey in China, the proportion of herbal users among patients with ALS exceeds 90% (Pan et al., 2013b), and the corresponding proportion is 40% in America (Vardeny and Bromberg, 2005). Nevertheless, the HMs get both praise and blame along with their widespread use. The effects of HMs have been continuously praised in ALS animal models and *in vitro*. *Bojungikgi* formula improved muscle and spinal cord function (Cai et al., 2019), *Shenqi Fuzheng* injection extended the overall survival and improved the pathological manifestations in the brain (Sugimoto et al., 2021), and *Huoling Shengji* formula significantly prolonged lifespan and prevented motor neuron loss (Zhou et al., 2018). Additionally, published clinical trials have enhanced the credibility of the experimental evidence. However, many RCTs of proposed HMs have failed to show positive results in the past 20 years. Furthermore, certain HMs have been linked with poorer prognosis in patients with ALS in a single-centre cohort study (Chen et al., 2015). This phenomenon confuses both the researchers and patients about whether the effect of HM is fair or whether it should be blamed for the design of RCTs for ALS.

Consequently, we performed a systematic review and meta-analysis of the published literature to explore whether HM may usefully improve the activity limitation and whether the safety evidence of HM for ALS can be established.

2 Methods

2.1 Protocol and registration

This systematic review was registered prospectively with PROSPERO: CRD42021277443. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (Page et al., 2021). Ethical approval was not required for this study.

2.2 Eligibility criteria

2.2.1 Types of studies

The RCTs were included irrespective of language and publication status.

2.2.2 Types of participants

Adults diagnosed with ALS, regardless of sex or ethnicity, were eligible. The diagnostic criteria based on all versions of consensus criteria including the El Escorial criteria (Brooks, 1994), the revised El Escorial criteria (Brooks et al., 2000), the Awaji algorithm (de Carvalho et al., 2008), or the Gold Coast criteria (Shefner et al., 2020) were acceptable. The adapted diagnostic criteria on the basis of these standards and commonly used in various countries were allowed.

2.2.3 Types of interventions

HMs in any form were included. Our definition of HMs includes herbs, herbal materials, herbal preparations, and finished herbal products that contain active ingredient parts of plants, other plant materials, or combinations, according to the World Health Organization (The World Health Organization, 2021). The comparators could be as follows: placebo, other pharmacological interventions such as Riluzole or Edaravone, or non-pharmacological intervention such as acupuncture or massage, when these interventions were administered as comparators or equally to all arms in trials.

2.2.4 Types of outcome measures

Any effect-related outcomes were measured. The primary outcome was activity limitation, measured with validated instruments such as the ALS Functional Rating Scale
(ALSFRS) (The ALS CNTF treatment study (ACTS) phase I-II Study Group, 1996), revised ALSFRS (ALSFRS-R) (Cedarbaum et al., 1999), or the modified Norris Scale (Norris et al., 1974). The secondary outcomes included tracheostomy-free survival (Paganoni et al., 2014) or overall survival, loss of strength (respiratory muscles and limb muscles), QOL, functional status, motor neuron loss, measurements based on traditional medicine theory, and pharmacodynamic biomarkers. The tracheostomy-free survival is defined as time to death, tracheostomy, or permanent non-invasive positive pressure ventilation, which shows end-of-life care for patients with ALS (Paganoni et al., 2014). The deficits of respiratory muscles are commonly assessed via forced vital capacity (FVC), and limb muscles are quantitatively evaluated by hand-held dynamometry (HHD) or Medical Research Council Scale (MRC). The change of QOL captured using validated instruments, such as the ALS Assessment Questionnaire-40 (ALSAQ-40) (Jenkinson et al., 1999), the ALS Specific Quality of Life-revised (ALSSQL-R) (Simmons et al., 2006), the MOS Item Short-form Health Survey (SF-36) (Ware and Sherbourne, 1992), or the Barthel index, during the treatment was evaluated. Validated scales assessing the functional status, such as the Appel ALS Score (AALSS) (Appel et al., 1987), were included. The motor neuron loss measured via motor unit number estimation (MUNE) or other neurophysiological tests was assessed. The MUNE is a measure of remaining motor units and, therefore, an indirect measure of motor neuron loss. Any data of pharmacodynamic biomarkers such as the neurofilament light chain were abstracted. For safety assessment, any adverse events (AEs) and serious adverse events (SAEs) were summarized.

### 2.3 Search strategy

Nine databases, including MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, Sinomed, National Institute of Informatics Support Academic Information Services (CNii), and Korean Journal Database (KCL), were retrieved respectively from their inception dates to 25 March 2022. Relevant grey literature sources such as reports, dissertations, theses, and conference abstracts were identified to reduce the risk of publication bias.

The on-going trials and unpublished studies were searched via the following registers: ClinicalTrials.gov; the World Health Organization International Clinical Trials Registry Platform (ICTRP); Chinese Clinical Trial Registry (ChiCTR); EU Clinical Trials Register; Clinical Research Information Service (CRIS), Republic of Korea; Japan Primary Registries Network (JPRN).

The searched terms were as follow: “amyotrophic lateral sclerosis,” “motor neuron disease,” “Lou Gehrig’s disease,” “Charcot disease,” “phytotherapy,” “traditional medicine,” “medicinal plant,” “herbal medicine,” “plant extract,” “plant preparation,” “traditional Chinese medicine,” “Chinese drug,” “Chinese formul,” “Chinese prescri,” “kampo medicine,” “Chinese materia medica,” “Japanese medicine,” “Japanese drug,” “Japanese formul,” “Japanese prescri,” “korean medicine,” “korean drug,” “korean formul,” “korean prescri,” and “randomised controlled trial.” The search strategies are listed in Supplementary Appendix A1. To highly identify RCTs, the Cochrane sensitivity-maximizing filter for RCTs (2008 revision in Ovid format) was adopted (Lefebvre et al., 2021).

### 2.4 Study selection and data extraction

According to prespecified selection criteria, two authors (YBS and XRG) reviewed the titles and abstracts of retrieved articles after duplicates were removed. The articles that did not fulfill the inclusion criteria were removed. The remaining articles were screened with full text by the same two authors independently. Any disagreements in primary and full-text screening were discussed to be resolved. A third review author (CZ) was consulted if required. All exclusion reasons were recorded.

For eligible articles remaining after the primary and full-text screening, two authors (YBS and QYJ) extracted the eligibility criteria, study design, participants, interventions, comparators, outcomes, results, and other relevant information using standard data extraction templates. For studies reporting results at more than one time point, the final data of the intended treatment period was mainly extracted. The same scheme resolved the disagreements. The multiple publications of the same study were listed under the original article. The missing information from the included studies was obtained via contact with the authors to reduce the reporting biases. The reference lists of all relevant primary studies were checked for other potential studies.

In addition to identifying potential benefits, possible AEs were also extracted, including liver injury, kidney damage, gastrointestinal dysfunction, allergy, skin discomfort, cardiovascular events, and any SAEs.

### 2.6 Strategy for data synthesis

Statistical analysis was performed using software provided by the Cochrane Collaboration (Review Manager 5.3). Relevant characteristics of studies were compared to assess which studies were eligible for each synthesis (Table 1). For continuous outcomes, the mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval (CI) was calculated depending on the similarity of outcome measurements. MD would be selected when studies all reported the outcome using the same scale. The relative risk (RR) with a 95% CI was calculated for dichotomous outcomes.
| Study | Certainty of ALS | N Participant Tested | Allocation | Duration, months | Outcome measures | Study design |
|-------|------------------|----------------------|------------|----------------|-----------------|-------------|
| Bao et al. (2016) | A + B + C + D | 24; unclear, 24, 48.5 (9.7) | Juweii Sijunzi formula $+_{TT}$ conventional treatment | 6 | STMS, AE | OL |
| Cai (2011) | Unclear | 20; 51.2 (11.7) | Shenmai injection $+_{TT}$ conventional treatment | 1.8$^b$ | ALSFRS/ALSFRS-Rc | OL |
| Chico et al. (2018) | A + B + C + D | 18; 48.5 (9.7) | Curcumin $+_{TT}$ | 3 | ALSFRS-R, HHD, MRC, PB, AE | DB |
| Jin (2013) | A + B + D | 15; 50.5 (18.9) | Guili Erxian glues + acupuncture $+_{TT}$ Riluzole | 6 | ALSFRS-R, STMS, AE | OL |
| Li et al. (2011) | A + B + C + D | 30; 56.4 (11.1) | Fuyuan Shengji granule $+_{TT}$ Riluzole | 6 | Modified Norris Scale, FVC, tracheostomy-free survival | OL |
| Li (2019a) | A + B + D | 39; 51.1 (10.3) | Juweii Yifei formula + massage $+_{TT}$ Riluzole | 3 | ALSFRS, AALSS, STMS | OL |
| Ma et al. (2006) | A + B + D + E | 30; 48.7 (11.1) | Juweii Yifei formula + massage $+_{TT}$ Riluzole + dummy Riluzole | 3 | ALSFRS, Modified Norris Scale, FVC, AALSS, ALSAQ-40, FVC, VC, MUNE, AE | DB |
| Pan et al. (2018a) | A + B | 24; 51.6 (7.2) | Juweii Sijunzi formula $+_{TT}$ Riluzole | 6 | ALSFRS-R, MRC, SF-36 (sub), AE | OL |
| Pan (2015) | A + B + D | 40; 49.4 (9.0) | Shenche Jiangqi powder $+_{TT}$ dummy Riluzole | 3 | ALSFRS, Modified Norris Scale, ALSAQ-40, MUNE, AE | DB |
| Riva et al. (2019) | A + B + C | 30; 57.2 (13.8) | Cannabisinoids $+_{TT}$ placebo | 1.5 | ALSFRS-R, FVC, MRC, Barthel index, AE | DB |
| Su et al. (2006) | A + B + C + D | 25; 60.2 (14.1) | Yai Quangqi formula $+_{TT}$ Riluzole | 3 | Modified Norris Scale, STMS, CMAP | OL |
| Su et al. (2016) | A + B + C + D | 33; 54 (12.0) | Huiling Shengji formula $+_{TT}$ Riluzole | 3 | Modified Norris Scale, STMS, AE | OL |
| Wang (2007) | A + B + C + D | 30; 44.6 (9.6) | Juweii Yifei formula + massage $+_{TT}$ Riluzole | 3 | ALSFRS, ALSAQ-40, FVC, VC, MUNE, PB, AE | OL |
| Wang et al. (2009) | A + B + C + D | 100; 55.1 (13.5) | Fuyuan Shengji granule $+_{TT}$ Riluzole | 3 | Modified Norris Scale, STMS, CMAP, PB, AE | OL |
| Wang 2017a | A + B + C + D | 30; 56.6 (11.2) | Juweii Shugan formula $+_{TT}$ Riluzole | 2 | ALSFRS-R, MRC, FVC, AE | OL |
| Wang 2017b | A + B + C + D | 30; 48.8 (3.8) | Juweii Shugan formula $+_{TT}$ conventional treatment | 1 | ALSFRS, Barthel index, STMS, AE | OL |
| Xe et al. (2011) | A + B + D | 40; 60$^a$ | Juweii Shugan formula $+_{TT}$ Riluzole | 6 | Modified Norris Scale, STMS | OL |

(Continued on following page)
Trials were excluded from the synthesis when essential data were missing.

Both random-effect models and fixed-effect models were performed in meta-analysis when available. The results from both models were reported when significant heterogeneity existed, and the heterogeneity was tried to explain by subgroup if applicable. When there was no significant heterogeneity, the results of the fixed-effect model were reported. When the heterogeneity was substantial, both models were abandoned, and the meta-analysis was replaced by the qualitative summary. The heterogeneity was calculated with the I² test. To visually display the results of syntheses, forest plots were constructed. We planned the subgroups classified by disease course and different durations of intervention. We projected to perform the sensitivity analysis using the following filters: certainty of ALS and risk of bias.

2.5 Risk of bias assessment

Two review authors (YBS and QYJ) assessed the risk of bias independently using the Cochrane Handbook for Systematic Reviews of Interventions (Revised Cochrane risk-of-bias tool for randomised trials) for eligible studies (Sterne et al., 2019). The bias domain of the randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, selection of the reported result, and other biases were evaluated. A judgment of bias was made and divided into "low risk," "high risk," and "some concerns." Unclear items in studies were further checked by contacting the corresponding authors. Any disagreements were discussed with a third reviewer (CZ). Funnel plots were constructed to evaluate the publication bias across studies when at least ten studies were included in the quantitative analysis synthesis.

The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used by two reviewers (QYJ and YBS) to separately assess the certainty of evidence for each outcome. The discrepancies were resolved by discussion with a third reviewer (XRG).

3 Results

3.1 Results of the search

A total of 489 records were retrieved. Of these trials, one was identified from the register and has been completed. 384 records remained after duplicates were removed. After titles and abstracts were screened, 331 records were excluded due to non-clinical trials, non-herbal interventions, or non-ALS participants. After reading the full text, 31 trials were excluded, and the reasons were listed in Supplementary Appendix A2. Before the manuscript was submitted, we updated retrieval, but no additional trials meeting inclusion criteria were found. Therefore, 20 RCTs were included. The PRISMA flowchart of study selection is presented in Figure 1.

3.2 Included studies

The characteristics of 20 included RCTs are listed in Table 1. All included trials adopted parallel two-arm designs. Five studies were double-blinded (Ma, 2006; Pan, 2015; Zhu, 2016; Chico et al., 2018; Riva et al., 2019), and other studies were open-
labelled. Three trials were published in English (Pan et al., 2013a; Chico et al., 2018; Riva et al., 2019), and others were reported in Chinese. Two included studies were conducted in Italy (Chico et al., 2018; Riva et al., 2019), and the rest were in China. Only three trials reported the sample size calculation (Fang, 2016; Zhu, 2016; Riva et al., 2019).

### 3.3 Participants

The number of participants in each included trial ranged from 28 to 125, with a total of 1,218 investigated subjects (655 were in the treatment groups, and 563 were in the control groups). Of them, 838 (68.8%) participants were male sex. There were nine trials including subjects on the basis of both ALS diagnostic criteria and traditional medicine signs. Two trials did not describe inclusion and exclusion criteria (Su et al., 2006; Cai, 2011). One trial did not report whether baseline characteristics were well matched between groups or not (Su et al., 2006).

### 3.4 Interventions

Among the twenty included trials, fourteen HMs (Supplementary Appendix A3) were investigated. Most were herbal preparations, and only four were patent herbal productions (Cannabinoids, Curcumin, Jiweiling injection, and Shenmai injection). One HM was delivered via an oromucosal spray (Riva et al., 2019), two were administered intravenously (Ma, 2006; Wang, 2007; Cai, 2011; Zhang, 2020), and the other eleven HMs were taken orally. The fourteen HMs contained fifty-one single botanicals (Supplementary Appendix A3); *Astragalus mongholicus* Bunge, Atractylodes macrocephala Koidz., Glycyrrhiza glabra L., Poria cocos (Schw.) Wolf., and *Codonopsis pilosula* (Franch.) Nannf. Were commonly used in nine, eight, six, and five trials, respectively. One trial did not describe the procedure of medicine preparation. One trial investigated HM combined with acupuncture (Jin, 2013), and another combined with massage (Li P., 2019). The duration of treatments ranged from 1 month to 9 months, and most trials (nine trials) investigated participants for 3 months (Table 1).

### 3.5 Comparators

Two studies compared HM with placebo (Chico et al., 2018; Riva et al., 2019). Eight studies compared HM with Riluzole (Ma, 2006; Wang, 2007; Wang et al., 2009; Xv et al., 2016; Pan et al., 2013a; Pan, 2015; Fang, 2016; Sui et al., 2016). Four studies conducted Riluzole add-on therapy for ALS (Su et al., 2006; Li et al., 2011; Jin, 2013; Wang et al., 2017). Five studies adopted conventional treatment add-on therapy (Cai, 2011; Bao et al., 2016; Wang, 2017; Li, 2019b; Zhang, 2020). One study used 1/10 dose of investigated medicine as a placebo, thus was classified as a dose-response controlled trial (Zhu, 2016) (Table 1).

### 3.6 Risk-of-bias assessment

The quality assessment of each study’s random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other bias are presented in Figures 2, 3. We were not able to detect publication bias for any analysis.

### 3.7 Effects

#### 3.7.1 Activity limitation

A total of 19 studies (N = 1,045, Supplementary Appendix A4) measured activity limitation. Significant differences were found between intervention and controls.

Fourteen trials reported changes in activity limitation measured with the ALSFRS-R or the ALSFRS. As the modified Norris Scale is less sensitive than the ALSFRS-R, it has fallen out of favour (Paganoni et al., 2014). But five trials still employed it as the measure of activity limitation (Su et al., 2006; Wang et al., 2009; Li et al., 2011; Xv et al., 2011; Sui et al., 2016).
Two trials used both the ALSFRS and modified Norris Scale (Ma, 2006; Pan, 2015).

Of the 19 trials, nine reported better effects of treatment than controls (Supplementary Appendix A4), among which four trials employed the ALSFRS-R (Jin, 2013; Zhu, 2016; Wang et al., 2017; Zhang, 2020); three trials measured with the ALSFRS (Ma, 2006; Wang, 2007; Pan, 2015), even though these trials were conducted after the ALSFRS-R (revised version of ALSFRS) has been applied in clinical studies regularly; one trial did not mention the accurate version of ALS Function Rating Scale (Cai, 2011); one trial measured with the modified Norris Scale (Li et al., 2011).

In pooling analysis, fixed-effect models were used and were good fits to the data. For delaying activity limitation, Jiweiling injection ([Araliaceae; Panax ginseng C. A. Mey.] and [Apiaceae; Angelica sinensis (Oliv.) Diels]) (MD, 2.84; 95% CI, 1.21 to 4.46; p = 0.0006) (Ma, 2006; Wang, 2007) and Shenmai injection ([Araliaceae; Panax ginseng C. A. Mey.] and [Asparagaceae; Ophiopogon japonicus (Thunb.) Ker Gawl.]) (SMD, 1.07; 0.69 to 1.45; p < 0.00001) (Cai, 2011; Zhang, 2020) were significantly more efficacious than controls (Figures 4, 5). However, the insufficient number of homogeneous trials did not allow the subgroup analysis and sensitivity analysis.

Another 10 trials showed no statistically significant differences between treatments and controls. Four of them were measured with the ALSFRS-R (Pan et al., 2013a; Fang, 2016; Chico et al., 2018; Riva et al., 2019) and 2 with ALSFRS (Wang, 2017; Li P., 2019). In the Curcumin trial (Chico et al., 2018), the author also analysed the sub scale of the ALSFRS-R (question 10–12) for respiratory assessment, and the significant result was found. However, this article did not report any specific data for synthesis. Another three trials measured the modified Norris Scale (Su et al., 2006; Wang et al., 2009; Xv et al., 2011; Su et al., 2016).
3.7.2 Survival

Only one trial (N = 58, follow-up for 18 months, Supplementary Appendix A4) reported tracheostomy-free survival but did not show a significant difference between treatment and control (Jin, 2013). This trial displayed the Kaplan-Meier survival curve but did not report the Hazard ratio and 95% CI.

3.7.3 Loss of strength

Seven studies (N = 738, Supplementary Appendix A4) assessed the loss of strength. Meta-analysis was replaced by the qualitative summary due to substantial heterogeneity [I^2 = 75% in pooling analysis of respiratory function measured with FVC; I^2 = 81% when measured with the vital capacity (VC)].

Five trials measured FVC (Ma, 2006; Wang, 2007; Li et al., 2011; Wang et al., 2017; Riva et al., 2019). Two of them showed statistical significance in delaying the decline of ventilatory muscle strength (Ma, 2006; Wang, 2007). These two trials also showed significant differences when measuring VC. Another three trials showed no statistical significance (Li et al., 2011; Wang et al., 2017; Riva et al., 2019).

Four trials evaluated MRC (Pan et al., 2013a; Wang et al., 2017; Chico et al., 2018; Riva et al., 2019), and all of them did not show significant effects. Of these, the Curcumin trial (Chico et al., 2018) also used HHD to measure the accurate grip force.

3.7.4 Quality of life

Seven trials (N = 394, Supplementary Appendix A4) evaluated the QOL. Three reported significant difference between treatment and control when measuring the ALSAQ-40 (Ma, 2006; Wang, 2007; Pan, 2015). Additionally, one trial measuring the subscale of ALSAQ-40 reported no significant effect (Fang, 2016).

Two trials employed the Barthel index; one showed a significant effect (Wang, 2017), and another showed no significant difference (Riva et al., 2019). One trial (Pan et al., 2013a) reported results on the subscale of the SF-36 and found no significant improvement.

3.7.5 Functional status

Two trials (N = 138, Supplementary Appendix A4) assessed the functional status of ALS patients via the AALSS. Of them, one showed a statistically significant difference (Ma, 2006), and another reported no significant effect (Li, 2019b).

3.7.6 Score of traditional medicine syndrome

Nine trials (N = 560, Supplementary Appendix A4) recorded the change in symptoms and signs based on traditional medicine theory (Su et al., 2006; Wang et al., 2009; Xv et al., 2011; Jin, 2013; Bao et al., 2016; Sui et al., 2016; Zhu, 2016; Wang, 2017; Li, 2019b), and only one of them reported no significant improvement compared to control (Li, 2019b). However, most
measurements used in these trials lack verification of reliability and validity.

3.7.7 Motor neuron loss

Three trials (N = 170, Supplementary Appendix A4) reported the change in MUNE (Ma, 2006; Wang, 2007; Pan, 2015) and all showed statistical significance.

The MUNE detected from the right and left abductor pollicis brevis (APB) were pooled respectively in our analysis to reduce the heterogeneity, and the results favoured Jiweiling injection (right APB: MD, 32.42; 7.91 to 56.93; p = 0.01; left APB: MD, 34.44; 12.85 to 56.03; p = 0.002) compared to Riluzole (Figure 6).

No subgroup or sensitivity analysis was conducted due to the insufficient number of trials.

Two trials (Supplementary Appendix A4) evaluated motor neuron loss using the amplitude of compound muscle action potential (Su et al., 2006; Wang et al., 2009), and they did not show better effects than controls.

Another trial (N = 78, Supplementary Appendix A4) used other electrophysiologic parameters related to muscle denervation and showed no statistical significance (Li, 2019b).

3.7.8 Pharmacodynamic biomarkers

Three trials (N = 221, Supplementary Appendix A4) measured five types of biofluid markers (a total of fourteen biomarkers): creatine kinase, oxidative stress biomarkers, neuron-specific enolase, amino acid, and immunoglobulin (Wang, 2007; Wang et al., 2009; Chico et al., 2018). The corresponding results of comparisons between treatments and controls are presented in Supplementary Appendix A4, and two trials reported significant differences (Wang, 2007; Chico et al., 2018). Unfortunately, no trials measured neurofilament, the most promising candidate biomarker at present.

3.8 Adverse events

A total of 14 studies (N = 845) evaluated the safety of treatments (Table 1). Of these, nine studies reported the occurrence of 123 adverse events (Table 2). 26 AEs happened in the treatment groups and 97 in the control groups. Of the 26 AEs, 2 SAEs (death) occurred in two trials that investigated Jiawei Sijunzi formula and Jianpi Yifei formula, respectively (Pan et al., 2013a; Fang, 2016). Two participants receiving Jianpi Yifei formula added on Riluzole were reported abnormal liver function (Wang et al., 2017). Gastrointestinal discomforts were found in a total of 17 individuals who were treated with Cannabinoids (N = 5) (Riva et al., 2019), Curcumin (N = 4) (Chico et al., 2018), Huoling Shengji formula (N = 3) (Sui et al., 2016), Jianpi Yifei formula plus Riluzole (N = 1) (Wang et al., 2017), and Jianwei SiJunzi formula (N = 4) (Pan et al., 2013a), respectively. Three participants taking Jianpi Yifei formula plus Riluzole developed skin allergies (Wang et al., 2017), and one patient receiving Curcumin had a skin rash (Chico et al., 2018). In addition, one patient who took Cannabinoids was reported cardiovascular disease.

3.9 Certainty of evidence

All outcome measurements for evaluation of function, survival, biofluid markers, and electrophysiological markers
were rated using GRADE. All included evidence was very low to low quality (Table 3). The risk of bias and imprecision were the reasons for downgrading all outcomes.

4 Discussion

4.1 Summary of findings

Twenty studies of HM for ALS were included. Whether these clinical trials are futile under the circumstances that so many efforts have been made but the effects of HMs are still being questioned. We systematically appraised published RCTs of HM for ALS to address this issue. Our results suggest that HMs may be effective for improvement in activity limitation, muscle strengths, QOL, functional status, traditional medicine syndromes, and motor neuron loss for individuals with ALS. However, only low and very low quality of evidence was available, which restricts the confidence that can be placed in the findings. Results of the meta-analysis revealed significant improvement in activity limitation (Jiweiling injection and Shenmai injection) and motor neuron loss (Jiweiling injection) when patients were treated with finished herbal productions. Nevertheless, the less number of trials brought into analysis reduce the reliability of the results to some extent. In addition, there was insufficient evidence of HMs prolonging survival.

Of these included herbal medicines, several possible therapeutic mechanisms were reported. Antioxidant was associated with the neuroprotective actions of ALS in Shenmai injection (She et al., 2013), Curcumin (Zhang et al., 2014), Guilu Erxian glues (Xv et al., 2013), Huoling Shengji formula (Zhou, 2017), and Jianpi Yifei formula (She et al., 2013; Li, 2019). In addition, Jiweiling injection plays a role in inhibiting calcium toxicity and anti-apoptosis (Wang, 2005). Cannabinoids exert effects on anti-inflammatory and antioxidant (Alexander, 2016). The pharmacologic mechanisms of the other seven HMs lack reports. However, Astragalus mongholicus Bunge, with properties of anti-aggregation of proteins and anti-inflammation (Zhang et al., 2014), is the main herb of four of them (Bushen Jianpi Shugan formula, Fuyuan Shengji granule, Jiawei Sijunzi formula, and Yiqi Qiangji formula). And ginseng, which has a neuroprotective effect against neuroinflammation and oxidative stress (Cai and Yang, 2016), is the main herb of Shenzhe Jiangqi powder.

When faced with significant evidence with very low to low quality, critical analyses may benefit the future clinical trials of HM for ALS. In the context of disease heterogeneity in ALS, the restrictive inclusion criteria for phase II and III clinical trials are
| Outcomes               | Measures                          | Participants, studies | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Certainty | Effect estimate* |
|-----------------------|-----------------------------------|-----------------------|--------------|---------------|--------------|-------------|----------------|-----------|-----------------|
|                       |                                   |                       |              |               |              |             |                |           |                 |
| **Activity limitation**| ALSFRS-R/ALSFRS                   | 721, 14               | Serious⁸     | Not serious   | Not serious  | Serious     | Undetected     | Low       | 25.38           |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | SMD: 0.64 more (0.47–0.80 more) |
|                       | Modified Norris Scale             | 438, 7                | Serious⁸     | Not serious   | Not serious  | Serious     | Undetected     | Low       | 58.22           |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | MD: 0.60 more (0.33–0.86 more) |
| **Survival**          |                                   | 58, 1                 | Serious⁸     | Not serious   | Not serious  | Serious     | Undetected     | Low       | n/N, 20/28      |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | Not significant, RR 1.12 (0.83–1.50)⁴   |
| **Loss of strength** | FVC                               | 291, 5                | Serious⁸     | Serious⁸     | Not serious  | Serious     | Undetected     | Very low  | 69.95%          |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | MD: 4.46% more (1.08–7.84% more) |
|                       | VC                                | 120, 2                | Serious⁸     | Serious⁸     | Not serious  | Serious     | Undetected     | Very low  | 68.08%          |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | MD: 5.35% more (2.34–8.36% more) |
| **MRC**               |                                   | 191, 4                | Serious⁸     | Not serious   | Not serious  | Serious     | Undetected     | Low       | 5.76            |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | Not significant, MD 0.04 more (0.28 fewer to 0.36 more) |
| **HHD**               |                                   | 36, 1                 | Serious⁸     | Not serious   | Not serious  | Serious     | Undetected     | Low       | NA             |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | NA              |
| **Quality of life**   | ALSAQ-40                          | 233, 4                | Serious⁸     | Not serious   | Not serious  | Serious     | Undetected     | Low       | 56.88           |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | ND             |
|                       | SF-36 (sub)                       | 42, 1                 | Serious⁸     | Not serious   | Not serious  | Serious     | Undetected     | Low       | 37.60           |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | Not significant, MD 0.80 more (3.20 fewer to 4.80 more) |
|                       | Barthel index                     | 119, 2                | Serious⁸     | Serious⁸     | Not serious  | Serious     | Undetected     | Very low  | 86.16           |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | MD: 3.67 more (0.06–7.28 more) |
| **Functional status**| AALSS                             | 138, 2                | Serious⁸     | Not serious   | Not serious  | Serious     | Undetected     | Low       | 84.02           |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | MD: 5.47 fewer (9.34–1.60 fewer) |
|                       | Traditional medicine syndrome     | 360, 9                | Serious⁸     | Serious⁸     | Serious⁸    | Serious     | Undetected     | Very low  | 15.29           |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | SMD: 0.81 fewer (1.04–0.38 fewer) |
| **Motor neuron loss**| MUNE                              | 230, 4                | Serious⁸     | Serious⁸     | Not serious  | Serious     | Undetected     | Very low  | 104.56          |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | MD: 34.75 more (18.74–50.76 more) |
|                       | CMAP                              | 35°, 2                | Serious⁸     | Not serious   | Not serious  | Serious     | Undetected     | Low       | 53.57           |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | Not significant, MD 1.00 more (0.84 fewer to 2.84 more) |
| **Pharmacodynamic**   | biomarkers                        | 221, 3                | Serious⁸     | Serious⁸     | Not serious  | Serious     | Undetected     | Very low  | 34.42           |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | ND             |
| **Adverse events**    |                                   | 845, 14               | Serious⁸     | Serious⁸     | Not serious  | Serious     | Undetected     | Very low  | n/N, 97/269     |
|                       |                                   |                       |              |               |              | Limitations⁹|                |           | RR: 0.28 (0.19–0.42) |

AALSS, appel amyotrophic lateral sclerosis score; ALSAQ-40, amyotrophic lateral sclerosis assessment questionnaire-40; ALSFRS, amyotrophic lateral sclerosis functional rating scale; ALSFRS-R, amyotrophic lateral sclerosis functional rating scale-revised; CMAP, compound muscle action potential; FVC, forced vital capacity; GRADE, the grading of recommendations assessment, development, and evaluation; HHD, hand-held dynamometry; MRC, medical research council scale; MUNE, motor unit number estimation; NA, not available; ND, not done; SF-36, MOS item short-form health survey-36; VC, vital capacity.

*We chose to combine studies with post intervention values here, and studies with changes from baseline were listed in Supplementary Appendix A4.

Hiding or binding was not used.

Small number of events, or confidence interval was too wide.

Small number of events, or confidence interval was too wide.

Point estimates varied widely across studies, confidence intervals showed minimal, the heterogeneity test was significant, or the I² was large.

The trials misunderstood the clinical meaning of the ALSAQ-40, thus the data synthesis was abandoned.

Lack of consistent and objective diagnostic criteria.

The number of participants in one of trials was unclear.

Whether all the decreases of biomarkers point to the same direction is uncertain.
becoming an important consideration (Kiernan et al., 2021). The stratification of patients at the time of recruitment according to their characteristics enables patients to be matched with suitable therapies. Our included HM studies were mainly small sample clinical trials and thus should have a higher requirement of recruiting homogeneous subjects. Instead, participants with little restriction on diagnostic certainties and disease course were recruited and treated without stratification. Nowadays, several prognostic models and tools have been proposed to optimize ALS trials, especially in the recruitment process (Westeneng et al., 2018; van Eijk et al., 2019; van Eijk et al., 2021). Under the circumstances that ALS clinical trials with large sample sizes are difficult to be carried out, employing these models to select appropriate populations of patients sensitive to HMs makes sense.

Concerning the treatments, some trials did not describe the source and concentration of herbal preparations (Supplementary Appendix A3). Moreover, our meta-analysis showed statistical significance when data from finished herbal products were used. These findings suggest that unspecific constituents and manufacturing processes may hinder objective HM efficacy evaluations and thus reduce the repeatability of HM tested in further clinical trials. In addition, most HM trials only investigated patients for 3 months or less (Table 1). Such a short duration is not long enough to provide confirmatory evidence.

Regarding the comparators, in order to reduce unnecessary exposure to placebos, eight studies compared investigated HMs with Riluzole. However, such a design hampers the recognition of HM’s net effect. The master protocol (Kiernan et al., 2021), a strategy aiming to minimize unnecessary exposure to placebo and allowing for the simultaneous evaluation of multiple treatments with a shared placebo group, is a promising approach to address this issue. In addition, the Food and Drug Administration recommends the consideration of add-on designs in ALS clinical trials (The Food and Drug Administration, 2019), which is another choice to comply with the ethical criteria.

In terms of the selection of outcome measures, some limitations were identified. First, the ALSFRS-R/ALSFRS is the most widely accepted outcome measure of activity limitation in ALS patients (Gordon et al., 2007; Cudkowicz et al., 2014; Abe et al., 2017; Paganoni et al., 2020). However, about one-fourth of the included trials measuring activity limitation did not employ them but used the modified Norris Scale instead, which is less favourable at present. Furthermore, most HM clinical trials did not measure survival in consideration of disease heterogeneity, variation in the expected disease course, and high cost due to extended follow-up. However, the comparison of the design of clinical trials between Riluzole (Bensimon et al., 1994; Lacomblez et al., 1996) and Edaravone (Abe et al., 2017) shows that an increased life expectancy leaves little doubt about a treatment’s therapeutic potential. Thus, the benefits of measuring survival time in HM clinical trials may outweigh the disadvantages. Additionally, incorporation of optimized biomarkers into early-stage clinical trials is in prospect. Inspiringly, some of the included studies measured biofluid markers or electrophysiological markers and even drew significant conclusions, which benefits the understanding of pharmacological mechanisms. Rapid advances in the detection of the molecular biology and pathology of ALS are making the novel biomarker constantly emerge but also leading to the phenomenon that various biomarkers are employed without a uniform standard. Meanwhile, reliable biomarkers are badly needed for monitoring the response to treatment, but the consensus about the robust candidates has not yet been established, even though some high-quality publications have made recommendations (Grossman et al., 2014; Benatar et al., 2018; Magen et al., 2021), and certain biomarkers, such as the neurofilament light chain, have been already used in multicentre clinical trials (Paganoni et al., 2020). In addition, it is found that two studies (Ma, 2006; Wang, 2007) misunderstood the clinical meaning of the ALSAQ-40. Therefore, we abandoned the relevant data synthesis, even if they were homogenous and claimed to be effective.

Furthermore, other flaws in methodology could also hinder the recognition of the efficacy of HMs. Fifteen studies employed an open-labelled design because of common difficulties in imitating the smell and appearance of dummy herbal products, especially the peroral dosage form, which increased the information bias. Notably, most included studies claimed to be RCTs. However, the investigators did not sufficiently describe details related to the sample size calculation, randomization process, implementation of blinding, or measurement outcomes. Hence, reporting in detail according to the Consolidated Standards of Reporting Trials (CONSORT) Statement is urgently needed. Additionally, one study used a 10th of the dose of the investigated medicine as the placebo. Such a methodological flaw dramatically reduced the reliability of the study’s evidence.

Some inherent limitations in HM clinical trials mentioned above are hard to be remedied in the short run. A registration study with heterogeneous populations and long-term follow-up can bring researchers and patients objective and comprehensive knowledge about disease trajectory and even effectiveness of HMs via statistical methods. Such a study has been established in mainland China to investigate the properties of ALS patients who take HM (CARE-TCM) (Song et al., 2022). In addition, we had noticed that a new HM called TJ-68 (Shaoyao Gancao formula) was expected to be tested in an N-of-1 study and the RCT of Huoling Shengji formula was on-going while this manuscript was drafting. More evidence derived from well-designed trials may update our understanding of HM for ALS.

Some evidence shows more extensive involvement of pathological changes in ALS than previously recognized, such as cognitive dysfunction, emotional instability, and insomnia (Sedda, 2014; Boentert, 2020; Pender et al., 2020). It is found that these symptoms related to the extra-motor system are not rare concomitant behaviours and directly
impact QOL even though they hardly threaten survival. This systematic review aimed to appraise the effects of HMs on motor system symptoms. Further reviews summarizing the therapeutic effects of HMs for extra-motor system symptoms are needed.

Nine of twenty studies reported AEs, and two reported SAEs (Table 2). The occurrences of AEs, such as liver dysfunction, and SAEs, such as death, were more frequent in the control groups.

4.2 Limitations

This systematic review had some limitations. First, a large number of potential descriptors for HM hinder the design of a search strategy, even though we have used the Cochrane sensitivity-maximizing filter for RCTs to highly identify clinical trials. Second, the less number of trials with a small sample size included in the meta-analysis reduces the reliability of the pooled results. Third, the lack of data from on-going trials may alter the results dramatically.

5 Conclusion

HMs may play a role in delaying decline in function, and the evidence for the role in extending survival was insufficient. The very low to low quality of evidence requires further RCTs that have adequate methods, use placebos as controls, select appropriate participants, and employ efficient outcome measures.

6 Amendments to information provided at registration

We reviewed the results of measurements based on traditional medicine theory, which was not stated at registration.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author contributions

YG, CZ, and YS designed the study and organized the team. CZ and LF provided methodological direction. YG, SK, and JL gave clinical suggestions. YS, QJ, and XG conducted study selection, data extraction, assessment of the risk of bias, and evaluation of the evidence certainty. YS completed the report writing and analysis. WD revised the language. CZ revised the draft. YG supervised this project. All authors have read and approved this manuscript.

Funding

This study was funded by the National Foreign Expert Project (Grant No. QN2021110001L), the Chinese Medicine Inheritance and Innovation Talent Project Leading Talent Support Program of National Traditional Chinese Medicine (Grant No. 2018, 12), the Beijing University of Chinese Medicine Project (Grant No. 2019-JYB-XS-165), and the Beijing University of Chinese Medicine Project (Grant No. 2020-tsxk-001).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.946548/full#supplementary-material

References

Abe, K., Aski, M., Tsuji, S., Itoyama, Y., Sobue, G., Togo, M., et al. (2017). Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16 (7), 505–512. doi:10.1016/s1474-4422(17)30115-1

Alexander, S. P. (2016). Therapeutic potential of cannabis-related drugs. Prog NeuroPsychopharmacol Biol Psychiatry 64, 157–166. doi:10.1016/j.pnpbp.2015.07.001

Appel, V., Stewart, S. S., Smith, G., and Appel, S. H. (1987). A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience. Ann. Neurol. 22 (3), 328–333. doi:10.1002/ana.410220308

Bao, J., Fu, M., Shen, B., and Zhu, X. (2016). Treatment of amyotrophic lateral sclerosis with Jiawei Sijunzi decoction. Her. Med. 35 (51), 43–45. doi:10.3870/jam.1004.0781.2016.e1.021

Song et al. 10.3389/fphar.2022.946548
Benatar, M., Wuu, J., Andersen, P. M., Lombardi, V., and Malapina, A. (2018). Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and conversion. Ann. Neurol. 84 (1), 130–139. doi:10.1002/ana.23276

Bensimon, G., Lacomblez, L., and Meiningier, V. (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 330 (9), 585–591. doi:10.1056/NEJM199403303300901

Boentert, M. (2020). Sleep and sleep disruption in amyotrophic lateral sclerosis. Curr. Neurol. Neurosci. Rep. 20 (17), 25. doi:10.1007/s11910-020-1047-1

Brooks, B. R. (1994). El escorial World federation of neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis. Other Mot. Neuron Disord. J. Neurol. Sci. 124, 96–107. doi:10.1016/0022-510x(94)90091-0

Brooks, B. R., Miller, R. G., Swash, M., and Munsat, T. L. (2000). Revised criteria for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Sci. 172, 103–125. doi:10.1016/s0022-510x(00)00210-5

Brooks, B. R., Miller, R. G., Swash, M., and Munsat, T. L. (2000). Revised criteria for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Sci. 172, 103–125. doi:10.1016/s0022-510x(00)00210-5

Brooks, C. H., et al. (2021). Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nat. Neurosci. 24 (11), 1534–1541. doi:10.1038/s41593-021-00986-z

Norris, F. H., Ir, Calanchini, P. R., Fellat, R. J., Pancioni, S., and Jewett, B. (1974). The administration of guanidine in amyotrophic lateral sclerosis. Neurology 24 (8), 721–728. doi:10.1212/wnl.24.8.721

Paganoni, S., Cudicoviz, M., and Berry, J. D. (2014). Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin. Invest. (Lond) 4 (7), 655–618. doi:10.1155/2014/124567

Pan, C. (2015). Clinical study on treatment of Chong meridian qi adversely ascending type amyotrophic lateral sclerosis by Shenzhen Juangzi Powder Master. Shijiazhuang: Hebei Medical University.

Pan, W., Chen, X., Bao, J., Bai, Y., Lu, H., Wang, Q., et al. (2013b). The use of integrative therapies in patients with amyotrophic lateral sclerosis in shanghai, China. Evid. Based. Complement. Altern. Med. 2013, 613596. doi:10.1155/2013/613596

Pan, W., Su, J., Bao, J., Wang, J., Zha, D., Cai, X., et al. (2013a). Open randomized clinical trial on WJSJX Decoction for the treatment of ALS patients. Evid. Based. Complement. Altern. Med. 2013, 347525. doi:10.1155/2013/347525

Pender, N., Pinto-Grau, M., and Hardiman, O. (2020). Cognitive and behavioural impairment in amyotrophic lateral sclerosis. Curr. Opin. Neuro. 33 (5), 649–654. doi:10.1016/j.copneu.2020.05.004

Riva, N., Mora, G., Sorati, G., Lunetta, C., Ferrando, O. E., Falzone, Y., et al. (2019). Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANAELS). A multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 18 (2), 155–164. doi:10.1016/s1474-4422(18)30406-x

Sedda, A. (2014). Disorders of emotional processing in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 27 (6), 659–665. doi:10.1097/WCO.0000000000000147

Shi, J., Xin, Y. F., and Xian, Y. X. (2013). Research Progress on the material basis of pharmacological action of Shenmai Injection. Her. Med. Sci. 32 (04), 497–500.

Shen et al., J. M., Al-Chalabi, A., Baker, M. R., Cui, L. Y., de Carvalho, M., Eisen, A., et al. (2020). A proposal for new diagnostic criteria for ALS. Clin. Neurophysiol. 131 (8), 1975–1978. doi:10.1016/j.clinph.2020.04.005

Simmons, Z., Felgusso, S. H., Bremer, B. A., Walsh, S. M., Huford, D. J., Bromberg, M. B., et al. (2006). The ALS/SSQOL: Balancing physical and nonphysical factors in assessing quality of life in ALS. Neurology 67 (9), 1659–1664. doi:10.1212/01.wnl.0000242887.97115.19

Song, Y., Li, M., Sugimoto, K., Han, Y., Liu, M., Ma, B., et al. (2022). China amyotrophic lateral sclerosis registry of patients with Traditional Chinese Medicine (CARE-TCM): Rationale and design. J. Ethnopharmacol. 284, 114774. doi:10.1016/j.jep.2021.114774

Sterne, J. A. C., Savovic, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., et al. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366, 14898. doi:10.1136/bmj.14898

Su, G., Zhang, J., and Hong, Y. (2006). Treatment of 25 cases of amyotrophic lateral sclerosis with Yiqi Qiangji Decoction. J. Ethnopharmacol. 118, 1–11. doi:10.1016/j.jep.2006.04.002

Song et al. 10.3389/fphar.2022.946548
Sui, S., Wang, Y., Zhi, H., Hong, Y., and Feng, Y. (2016). Clinical observation of Huoling Shengji formula in the treatment of amyotrophic lateral sclerosis. Acad. J. Shanghai Univ. Traditional Chin. Med. 30 (02), 23–26. doi:10.16306/j.1008-861x.2016.02.006

The ALS CNTF treatment study (ACTS) phase I-II Study Group (1996). The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch. Neurol. 53 (2), 141–147. doi:10.1001/archneur.1996.01550020045014

The Food and Drug Administration (2019). Amyotrophic lateral sclerosis-developing drugs for treatment guidance for industry. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry.

The World Health Organization (2021). Traditional Chinese medicine could make “health for one” true. Available at: https://www.who.int/intellectualproperty/studies/la.pdf?ua=1.

van Eijk, R. P. A., Nikolakopoulos, S., Roes, K. C. B., Kendall, L., Han, S. S., Lavrov, A., et al. (2021). Innovating clinical trials for amyotrophic lateral sclerosis: Challenging the established order. Neurology 97 (11), 528–536. doi:10.1212/WNL.0000000000012545

van Eijk, R. P. A., Nikolakopoulos, S., Roes, K. C. B., Middelkoop, B. M., Ferguson, T. A., Shaw, P. J., et al. (2019). Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry 90 (12), 1331–1337. doi:10.1136/jnnp-2019-320998

Vardeny, O., and Bromberg, M. (2005). The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS). J. Herb. Pharmacother. 5 (3), 23–31. doi:10.1080/157505303.03

Wang, A., Li, X., Ren, Z., Hou, X., Lu, M., and Du, B. (2017). Therapeutic effect of strengthening spleen and tonifying lung on amyotrophic lateral sclerosis. World Clin. Med. 12 (06), 1364–1367.

Wang, J., Gao, J., Guo, Y., Qin, B., Ren, H., Xv, W., et al. (2009). Clinical study of the effect of Fuyuan Shengji Granuleum on symptoms of the patients with amyotrophic lateral sclerosis. J. Neurology Neurorehabilitation 6 (03), 173–175.

Wang, J. M. (2005). Neuroprotective effect of Jiweiling injection on motor neuron disease. Doctor: Hebei Medical University.

Wang, W. (2017). Clinical observation on the treatment of motor neuron disease by nourishing kidney and strengthening spleen (liver-kidney yin deficiency type) Master. Beijing: Henan University of Chinese Medicine.

Wang, X. (2007). The clinical study of Jiweiling injection in dealing with amyotrophic lateral sclerosis bulbar paralysis Master. Hebei University.

Wang, X. (2007). The clinical study of Jiweiling injection in dealing with amyotrophic lateral sclerosis bulbar paralysis Master. Hebei Medical University.

Ware, J. E., Jr., and Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30 (6), 473–483. doi:10.1097/00005650-199206000-00002

Westeneng, H.-J., Debray, T. P. A., Visser, A. E., van Eijk, R. P. A., Rooney, J. P. K., Calvo, A., et al. (2018). Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. Lancet. Neurol. 17 (3), 423–433. doi:10.1016/S1474-4422(18)30089-9

Xv, W., Ren, H., and Zhi, H. (2011). Clinical observation on the treatment of amyotrophic lateral sclerosis by Tonifying the kidney, strengthening the spleen and soothing the liver. Acad. J. Shanghai Univ. Traditional Chin. Med. 25 (05), 46–49. doi:10.16306/j.1008-861x.2011.05.014

Xv, Y., Zhong, Y. Z., and Lin, S. Y. (2013). Experimental study and clinical application of Gaifu Erxian gue. Heilongjiang J. Traditional Chin. Med. 42 (06), 72–73.

Zhang, N. (2020). Effect of Shenmai Injection on patients with amyotrophic lateral sclerosis. Med. J. Chin. People’s Health 32 (8), 49–50. doi:10.3969/j.issn.1672-0369.2020.08.019

Zhang, X., Hong, Y. L., Xu, D. S., Feng, Y., Zhao, L. J., Ruan, K. F., et al. (2014). A review of experimental research on herbal compounds in amyotrophic lateral sclerosis. Phytother. Res. 28 (1), 9–21. doi:10.1002/ptr.4960

Zhou, Q. M. (2017). Neuroprotective therapy in amyotrophic lateral sclerosis model mice. Doctor: Shanghai Jiuotong University.

Zhou, Q., Wang, Y., Zhang, J., Shao, Y., Li, S., Wang, Y., et al. (2018). Fingerprint analysis of Huolingshengji Formula and its neuroprotective effects in SOD1G93A mouse model of amyotrophic lateral sclerosis. Sci. Rep. 8 (1), 1668. doi:10.1038/s41598-018-19923-9

Zhu, X. (2016). Exploratory study on the action mechanism of supplementary Siwuza Decoction in the treatment of amyotrophic lateral sclerosis. Doctor: Shanghai University of Chinese Medicine.